Skip to main content
OpenTrials
Completed

NCT Number: NCT04221269

Suicide Prevention Intervention for Schizophrenia-Spectrum Disorders

The current project is a pilot randomized controlled trial to test the Coping Long-term with Active Suicide Program for schizophrenia-spectrum disorders (CLASP-S) for patients following a psychiatric hospitalization. Participants will be assigned to enhanced treatment as usual (ETAU) alone vs CLASP-S plus ETAU. Participants complete assessments at baseline during their psychiatric hospitalization and at 3 months (mid-treatment) and 6 months (post-treatment) following discharge. The primary aim is to assess the feasibility and acceptability of CLASP-S. The secondary aim is to estimate the effects of CLASP-S on reducing suicidal thoughts and behaviors relative to ETAU.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Schizophrenia Behavior Behavioral Symptoms Mental Disorders Psychotic Disorders Schizophrenia Spectrum and Other Psychotic Disorders Self-Injurious Behavior Suicide Suicide Prevention

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Butler Hospital

Providence, Rhode Island, 02906, United States

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • suicidal thoughts or behaviors prior to hospital admission
  • diagnosis of a schizophrenia-spectrum disorder
  • receiving pharmacotherapy
  • 18 years or older
  • speaks/reads English

Exclusion criteria

  • psychosis due to substance use or medical condition
  • lack of phone access
  • discharge to long-term facility

Treatment and study plan

Enhanced Treatment as Usual

Behavioral

Routine community care plus assessment feedback reports to clinicians.

Coping Long-term with Active Suicide Program for Schizophrenia

Behavioral

Adjunctive psychosocial intervention for suicide prevention involving in person, family, and phone sessions.

Primary outcomes

  1. Client Satisfaction Questionnaire

    Time frame: 6 months

    The Client Satisfaction Questionnaire is a self-report measure of patient satisfaction with treatment. The total score (sum of items) will be used and ranges from 8 to 32 with increased scores indicating greater satisfaction with treatment.

Secondary outcomes

  1. Columbia Suicide Severity Rating Scale

    Time frame: 6 months

    The Columbia Suicide Severity Rating Scale is an interviewer-rated measure of suicidal thoughts and behaviors. The total score (sum of items) will be used and ranges from 2 to 25 with higher scores indicating higher suicidal thoughts and behaviors.

Sponsors and collaborators

Lead sponsor

Butler Hospital

Other

Collaborators

  • American Foundation for Suicide Prevention

Registry information

Official study title

Post-Hospital Suicide Prevention Intervention for Patients With Schizophrenia-Spectrum Disorders

Acronym: CLASP-S

Important dates

Study start
2020
Primary completion
2023
Study completion
2023
First posted
Jan 9, 2020
Registry last updated
Jul 11, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.